ArticleFrontiers in immunology2026
The obesity paradox in primary Sjögren's disease: immunometabolic associations of chemerin, platelet count, and statin use.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sjögren's disease is characterized by autoimmune destruction of exocrine glands. Obesity generally worsens the course of many diseases; however, earlier observations in our cohort suggested a paradoxically lower disease activity (ESSDAI) in overweight/obese patients. This cross-sectional study aimed to investigate potential mechanisms underlying these findings. Methods: Chemerin and oxidized low-density lipoprotein (oxLDL) levels were measured in a subset of regularly followed patients (n=75). Patients were stratified by body mass index (BMI): BMI <25 kg/m² ("non-obese", n=27) and BMI ≥25 kg/m² ("overweight/obese", n=48). Demographic, laboratory, and immunological parameters, disease activity (ESSDAI), extraglandular manifestations, and treatments were compared using biostatistical analyses. Results: Chemerin and oxLDL levels did not differ significantly between groups. ESSDAI was significantly lower in overweight/obese patients (5.04 vs. 2.76; p=0.04), while complement c3 levels were higher (1.20 vs. 1.46 g/L; p<0.001). Across all patients, chemerin positively correlated with BMI, age at diagnosis, c3, c4, CRP, platelet count, and leukocyte count. Hemoglobin and hematocrit were higher in overweight/obese patients, whereas neutrophil ratio was lower and lymphocyte ratio slightly higher. Statin therapy was also more frequent in the overweight/obese group (p=0.04). In this group, BMI and platelet count independently predicted chemerin levels, while platelet count predicted chemerin in normal-weight patients. Conclusion: Despite its positive correlation with BMI, chemerin levels were not significantly higher in overweight/obese patients, suggesting relatively lower levels. This may partly explain their more favorable immunological profile. Increased statin use may also contribute through anti-inflammatory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.